Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma

NCT07335679 | Recruiting

• 1 other identifier: 9693
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year. Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance (female-to-male ratio of 1.5). The majority of cases (\>90%) are sporadic, particularly in adults. ACC may be discovered incidentally during an imaging examination performed for another reason (10 to 20% of cases) or in connection with a tumor syndrome (40-60% of cases) or hormonal hypersecretion (40 to 74% of cases). The diagnosis of CCS can be suggested by the combination of morphological characteristics seen on imaging and clinical and biological features (secretory syndrome), but only histopathology allows for a definitive diagnosis. Furthermore, histopathology enables the assessment of aggressiveness criteria (Weiss score, Ki67), which will influence further management and prognosis. Given that CCS is a rare tumor, the investigators aim to study the clinical, biological, morphological, and histological characteristics and evaluate the prognosis of patients treated at our center in order to better understand the natural history of CCS and improve patient management.

Conditions

Adrenal Cortical Carcinoma

Keywords

Adrenal cortical carcinoma

Outcome Measures

Primary Outcomes (1)

• Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC)

  Overall survival: Is how long patients live after being diagnosed or treated, regardless of the cause of death. Example: If 100 patients are treated for ACC and 60 are alive after 5 years, the 5-year overall survival is 60%. It counts everyone, whether they die from ACC or something else, like an accident or another illness.

  Up to 12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

\- Adult subject (≥ 18 years old) followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025

You may qualify if:

• Adult subject (≥ 18 years old)
• Subjects followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025

You may not qualify if:

• \- Tumor reclassified as non-SCC by histopathology

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Adrenocortical Carcinoma

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Adrenal Cortex Diseases; Adrenal Gland Diseases; Endocrine System Diseases

Central Study Contacts

Philippe BALTZINGER, MD

CONTACT

33 3 88 12 75 82; philippe.baltzinger@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2026
• First Posted: January 13, 2026
• Study Start: June 10, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 10, 2027
• Last Updated: January 13, 2026

Record last verified: 2026-01

Locations

FR (1)